hyperglucagonemia

hyperglucagonemia

 [hi″per-gloo″kah-gon-e´me-ah]
abnormally high levels of glucagon in the blood.
References in periodicals archive ?
In 1966 McGavran et al [6] added to the symptoms hyperglucagonemia and their combination named as glucagonome syndrome (GS).
Insulin suppression is associated with hypersomatostatinemia and hyperglucagonemia in glucose-injected rainbow trout.
One possible explanation is the hyperglucagonemia that is present in diabetic animals [29].
Diabetes mellitus (DM) is a common metabolic disease characterized by hyperglycemia and metabolic disturbances of carbohydrates, proteins, and lipids principally caused by pancreatic [beta]-cell dysfunction, hyperglucagonemia, and increased renal glucose reabsorption [1, 2].
In their study, reversal of hyperglucagonemia by liraglutide or a glucagon-neutralizing antibody does not suppress increased hepatic gluconeogenic expression or improve blood glucose control but does attenuate ketosis in uncontrolled diabetes [41].
The cause of the disease is not clear, though zinc deficiency, hypoaminoacidemia and hyperglucagonemia have been proposed.
Decrease in [beta]-cell mass leads to impaired pulsatile insulin secretion, reduced postprandial hepatic insulin clearance, and relative hyperglucagonemia in the minipig.
As DeFronzo has highlighted, the accelerated lipolysis of fat cells, deficiency in incretin axis, hyperglucagonemia from a-cell hyperactivity, and increased glucose reabsorption in the kidney are all key components in the pathogenesis and progression of T2DM (22).
The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.
As described by Hoffman et al., [104] specific candidates for induction and stimulation of autophagy include insulin deficiency/resistance [105,106]; deficiency of insulin growth factor-1 (IGF-1) and insulin growth factor-1 receptor (IGF-1R) [104,107]; hyperglucagonemia [106]; and hyperglycemia [107].
Hung et al., "Chronic treatment with the AMP-kinase activator AICAR increases glycogen storage and fatty acid oxidation in skeletal muscles but does not reduce hyperglucagonemia and hyperglycemia in insulin deficient rats," PLoS ONE, vol.